The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
Official Title: A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
Study ID: NCT04600817
Brief Summary: A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Tongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
The Second Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
Tangdu Hospital of The Fourth Military Medical University of Chinese PLA, Xi'an, Shaanxi, China
Beijing Tiantan Hospital, Capital Medical University, Beijing, , China
Peking Union Medical College Hospital, Beijing, , China
Chongqiong Cancer Hospital, Chongqing, , China
Huashan Hospital Affiliated to Fudan University, Shanghai, , China
Tianjin Huanhu Hospital, Tianjin, , China
Tianjin Medical University Cancer Institute & Hospital, Tianjin, , China
Prince of Wales Hospital, Hong Kong, , Hong Kong